Veterinary-grade difloxacin is supplied in two principal forms: difloxacin free base and difloxacin hydrochloride monohydrate. The free base has the molecular formula C21H19F2N3O3, a molecular weight of 399.39 g/mol, and CAS 98106-17-3. The hydrochloride salt is commonly designated by CAS 91296-86-5 and is preferred for aqueous solution dosage forms because its dissolution rate in acidified vehicles is higher than that of the free base. The molecule carries a 4-fluorophenyl group at N-1 and a 4-methylpiperazin-1-yl group at C-7, distinguishing it from enrofloxacin and ciprofloxacin. The API is intended for processing into tablets, capsules, injectable solutions, powders, granules, premixes, and oral solutions under current good manufacturing practice for veterinary medicinal products. Grade designation typically reflects salt form, residual solvent profile, particle size, and microbial quality; no single grade is universally applicable to all seven dosage forms.

What Release Limits and Pharmacopoeial Methods Are Applied to Difloxacin Hydrochloride Before Formulation?

Assay, related substances, water content, residual solvents, elemental impurities, and microbiological quality are controlled before the API is released for veterinary use. High-performance liquid chromatography is the primary assay method; a representative acceptance criterion for difloxacin hydrochloride is 98.5–101.0% on the dried basis, with total related substances not more than 1.0% and any single specified impurity not more than 0.2%. Water content is determined by Karl Fischer titration; the monohydrate salt commonly carries a limit of not more than 3.0%, while the free base is specified at not more than 0.5%. Residual solvents are assessed under VICH GL18(R) and ICH Q3C(R8). Elemental impurities are controlled according to USP <232> and measured by procedures described in USP <233>. Injectable-grade material requires bacterial endotoxin testing using USP <85> or Ph. Eur. 2.6.14, with the limit calculated from the maximum intended dose and a parenteral threshold of 5 EU/kg unless a stricter national compendial limit applies.

For oral solid dosage forms, difloxacin hydrochloride is commonly blended with microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, and sodium starch glycolate before compression or encapsulation. Direct compression is feasible only when the API particle size distribution is controlled and the blend bulk density remains above approximately 0.45 g/cm³; otherwise, flow stratification and content uniformity drift are observed on rotary tablet presses. Wet granulation is used when higher API loading is required, but the granulation process should be limited to short exposure times and low moisture because fluoroquinolones can exhibit polymorphic instability and photodegradation under extended drying. For powders and granules intended for premix or oral solution reconstitution, geometric dilution with a spray-dried lactose or dextrose carrier is standard. The resulting premix is blended in V-blenders or bin blenders, and blend uniformity is evaluated by sampling at least 10 locations according to USP <905> or equivalent. Capsule filling on tamping-pin machines requires the powder plug to maintain a minimum hardness; excessive fines below 75 µm can increase fill weight variability and dust loss.

Particle-Size Distribution and Compression Behavior on Rotary Tablet Presses

Particle size control is critical because difloxacin hydrochloride is light-sensitive and electrostatic when micronized. A D90 within 20–100 µm is typical depending on the intended dosage form; micronized material below 20 µm improves dissolution and content uniformity in low-dose tablets but reduces flowability and increases tooling adhesion. On rotary tablet presses operating at compression forces from 8 kN to 18 kN, the main observed failure mode is capping when magnesium stearate is overmixed or when the granules are overdried below 1.0% moisture. Tablet hardness is maintained between 50 N and 100 N for immediate-release formulations; higher hardness slows disintegration and can delay release in aqueous media. Disintegration testing follows USP <701> with simulated gastric fluid without pepsin, and dissolution testing is performed using USP <711> apparatus 2 at 50 rpm in 900 mL of 0.1 M hydrochloric acid. Published difloxacin-specific dissolution data are limited; vendor certificates of analysis generally report a multi-point dissolution profile rather than a single-point figure.

Injectable solutions containing difloxacin hydrochloride are acidified to maintain solubility and chemical stability. The base is zwitterionic, with ionizable carboxylic acid and piperazinyl functions; the pH of minimum solubility lies between the two pKa values. A pH range of 3.5–5.0 is frequently used for fluoroquinolone injectable formulations, although the optimal range must be confirmed for the specific co-solvent and tonicity modifier. Methanesulfonic acid or hydrochloric acid is used for pH adjustment; sodium hydroxide should be added slowly to avoid local alkaline precipitation of the free base. The solution is protected from light, sparged with nitrogen, and filtered through a 0.22 µm sterilizing-grade membrane before filling. Terminal sterilization by autoclaving at 121°C for 15 min may be possible only after thermal stability of the finished formulation is demonstrated; published data for difloxacin hydrochloride under terminal sterilization are limited, and aseptic filtration is often selected as the conservative route. For oral solutions, the vehicle may contain sorbitol, glycerol, or propylene glycol, but the concentration of propylene glycol should be limited in food-producing species where regulatory restrictions apply.

When pH Control in Injectable Vehicles Is Limited by Zwitterionic Solubility

The free base has limited aqueous solubility at neutral pH, and the hydrochloride salt does not remain dissolved if the pH is raised above the zone of zwitterionic precipitation. Precipitation during dilution with isotonic saline or lactated Ringer’s solution is a known processing risk. To reduce this risk, the concentrated injectable solution is diluted into an acidic carrier or administered through an in-line filter with a compatible vehicle. The final solution should be visually inspected for haze and checked for subvisible particles using USP <788> or Ph. Eur. 2.9.19. If a phosphate buffer is used, the dibasic phosphate concentration must remain low; phosphate salts can reduce fluoroquinolone solubility through complex formation with polyvalent cations. The formulation is incompatible with aluminum- and magnesium-containing diluents because chelation between the fluoroquinolone carbonyl and carboxyl groups and trivalent or divalent metals can form poorly absorbed complexes. For parenteral administration, the final product is filled under nitrogen and stored in amber glass or opaque flexible containers because fluoroquinolones are susceptible to photochemical degradation to des-fluoro and ring-opened products.

The principal structural difference between difloxacin and enrofloxacin is the N-1 substituent: difloxacin carries a 4-fluorophenyl group, whereas enrofloxacin carries a cyclopropyl group. At C-7, difloxacin carries a 4-methylpiperazin-1-yl group, while enrofloxacin carries a 4-ethylpiperazin-1-yl group. These substitutions alter chromatographic retention, ionization constants, lipophilicity, and tissue distribution. Difloxacin is not a direct salt or derivative of ciprofloxacin, although both belong to the 6-fluoroquinolone class. The 4-fluorophenyl group at N-1 increases molecular weight and can reduce aqueous solubility at neutral pH relative to ciprofloxacin base, which affects formulation strategy. Difloxacin is not automatically interchangeable with enrofloxacin in food-producing species because national maximum residue limits and withdrawal periods are compound-specific. A formulator who replaces enrofloxacin with difloxacin must re-establish process parameters for blend uniformity, dissolution, and packaging because the two compounds differ in crystal habit, particle size distribution, and photostability.

For premix and granule applications, difloxacin hydrochloride is frequently incorporated at low mass fractions onto feed-grade carriers such as ground corn cob, soybean hulls, or lactose. The primary processing bottleneck is segregation during pneumatic conveying and screw feeding. The API should be milled to a particle size compatible with carrier adsorption; if the API is too coarse, assay variability increases across the premix, and if the API is too fine, dust formation creates cross-contamination risk. A two-stage geometric dilution sequence is standard, with the first blend prepared at a ratio of 1:1 to 1:5 and subsequent dilutions bringing the final concentration to the intended premix strength. Ribbon blenders with spray-bar addition of a binder solution may be used, but the moisture level should not exceed 3.0% unless stability data support higher residual water. The finished premix is tested for bulk density, tapped density, and loss on drying. Content uniformity is evaluated by assay of at least 10 unit samples, and the acceptance limits follow USP <905> or the regional veterinary codex.

Residual Solvent Control Under VICH GL18(R) and ICH Q3C(R8) Options

Residual solvent profiles depend on the synthetic route and final crystallization solvent. The API must comply with VICH GL18(R) for veterinary medicinal products, with ICH Q3C(R8) applied as a secondary reference. Class 1 solvents such as benzene and carbon tetrachloride are not detected. Class 2 solvents such as methanol, dichloromethane, and toluene are limited to their permitted daily exposure values. Class 3 solvents such as ethanol, ethyl acetate, and acetone are acceptable within the 0.5% threshold unless a higher limit is justified by toxicological data. Residual solvent testing is performed by headspace gas chromatography with flame ionization detection or mass spectrometry. The analytical method should be validated for specificity, limit of detection, and limit of quantitation under ICH Q2(R2) or the corresponding veterinary guidance. Drying under vacuum at a product temperature below 60°C is used to reduce residual solvent without degrading the API; higher drying temperatures may cause partial loss of the hydrochloride salt or formation of agglomerates.

Stability of difloxacin hydrochloride is governed by light, moisture, and pH. The API should be stored in tightly closed containers protected from light at controlled room temperature, typically 15–25°C. Under high-humidity conditions above 60% RH, the powder may adsorb moisture and become cohesive, reducing flow and increasing tablet weight variability. Pre-drying is required when the water content exceeds 2.0% for direct compression. Incompatibilities include strong oxidizing agents, alkaline buffers, and polyvalent metal ions. The API should not be combined with aluminum hydroxide, magnesium oxide, or iron-containing additives in oral dosage forms because chelation can reduce absorption. The processing area should maintain relative humidity below 50% RH and use opaque or amber containers for all milled material. Batch-to-batch variance in particle size and residual solvent content is controlled by specifying the final crystallization solvent and the milling method; jet-milled material exhibits higher surface energy and static charge but faster dissolution, whereas hammer-milled material flows better but may have broader particle size distribution.